<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02378805</url>
  </required_header>
  <id_info>
    <org_study_id>Alport-UMG2010</org_study_id>
    <nct_id>NCT02378805</nct_id>
  </id_info>
  <brief_title>European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome</brief_title>
  <official_title>European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Goettingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gesellschaft für Pädiatrische Nephrologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsche Gesellschaft für Nephrologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alport Selbsthilfe e.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KfH Foundation Preventive Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Goettingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hereditary type IV collagen disease Alport syndrome inevitably leads to end-stage renal
      disease. Currently there are no therapies known to improve outcome. Our non-interventional,
      observational study investigates, if medications such as ACE-inhibitors can (1) delay time to
      dialysis and (2) improve life-expectancy within three generations of Alport-families in
      Europe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early diagnosis in children with Alport syndrome (AS) with isolated hematuria opens a &quot;window
      of opportunity&quot; for early intervention. Currently there are no causal therapeutic options
      which are proven to delay renal failure in AS. ACE-inhibition (ACEi) has been shown to reduce
      proteinuria in Alport patients and to delay renal failure in Alport-mice suggesting it may be
      of value as an effective treatment to delay renal failure in humans. To test this we
      established the European Alport Registry to collect data over several generations of Alport
      families across Europe. Small children with AS first develop microscopic hematuria,
      proceeding to microalbuminuria, overt proteinuria, impaired renal function and end up with
      end stage renal disease. These different steps of disease enabled us to assess if earlier
      introduction of ACE-inhibition at earlier degrees of disease is more effective than later
      therapy in delaying the time to dialysis and improving life-expectancy.

      Heterozygous COL4A3/COL4A4 mutations result in the phenotype &quot;familial benign hematuria&quot; or
      &quot;thin basement membrane nephropathy&quot; (TBMN). Affected subjects typically present with
      hematuria. Having longtime been regarded as &quot;benign&quot; familial hematuria, those patients might
      have an increased risk to develop severe renal impairment - comparable to the findings in
      female XLAS carriers (see above). TBMN is not a rare disease, as at least 1% of the
      population is affected.

      For the first time, the present study compares the risk of renal impairment, end stage renal
      disease and premature death in between heterozygous carriers of XLAS and of ARAS mutations.
      Additionally, the nephroprotective effect of RAAS-blockade in patients with heterozygous
      Alport-mutations is evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 1995</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>end stage renal disease</measure>
    <time_frame>unlimited</time_frame>
    <description>Age at onset of end stage renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>life-expectancy</measure>
    <time_frame>unlimited</time_frame>
    <description>life-expectancy of patients and carriers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>proteinuria after initiation of ACE-inhibitor-therapy</measure>
    <time_frame>unlimited</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with a clinical diagnosis of hypertension</measure>
    <time_frame>unlimited</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients experiencing side effects from ACE-inhibitors</measure>
    <time_frame>unlimited</time_frame>
    <description>defined as acute renal failure (doubling of serum-creatinine), angioedema, hyperkalemia &gt;5.0 mmol/l, dry cough, symptomatic hypotension (orthostatic collapse) and others, and death from all causes.</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Alport Syndrome</condition>
  <condition>Hereditary Kidney Disease</condition>
  <condition>Pediatric Kidney Disease</condition>
  <condition>Thin Basement Membrane Disease</condition>
  <condition>Familial Benign Hematuria</condition>
  <arm_group>
    <arm_group_label>no-T: untreated patients</arm_group_label>
    <description>untreated patients, typically uncles or grandfathers of present patients. No Intervention (means no therapy until CKD stage V, on renal replacement therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-III: late therapy in patients</arm_group_label>
    <description>patients treated with RAAS-Blockade after onset of renal failure (GFR below 60 ml/min) (starts at patients with CKD stages III and IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-II: early therapy in patients</arm_group_label>
    <description>therapy starts at patients with proteinuria &gt;0.3 g/day or per gCreatinine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-I: very early tharpy in patients</arm_group_label>
    <description>starts at patients with microhematuria only (usually at birth) or microalbuminuria (30-300 mg protein per day or per gCreatinine in children).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no therapy in heterozygous carriers</arm_group_label>
    <description>heterozygous carriers without therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>therapy in heterozygous carriers</arm_group_label>
    <description>heterozygous carriers with RAAS-blockade</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE-inhibitor</intervention_name>
    <description>observational study!</description>
    <arm_group_label>T-III: late therapy in patients</arm_group_label>
    <arm_group_label>T-II: early therapy in patients</arm_group_label>
    <arm_group_label>T-I: very early tharpy in patients</arm_group_label>
    <arm_group_label>therapy in heterozygous carriers</arm_group_label>
    <other_name>Ramipril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT1-inhibitor</intervention_name>
    <description>observational study!</description>
    <arm_group_label>T-III: late therapy in patients</arm_group_label>
    <arm_group_label>T-II: early therapy in patients</arm_group_label>
    <arm_group_label>T-I: very early tharpy in patients</arm_group_label>
    <arm_group_label>therapy in heterozygous carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMG-Coenzyme inhibitor (statin)</intervention_name>
    <description>observational study!</description>
    <arm_group_label>T-III: late therapy in patients</arm_group_label>
    <arm_group_label>T-II: early therapy in patients</arm_group_label>
    <arm_group_label>T-I: very early tharpy in patients</arm_group_label>
    <arm_group_label>therapy in heterozygous carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>observational study!</description>
    <arm_group_label>T-III: late therapy in patients</arm_group_label>
    <arm_group_label>T-II: early therapy in patients</arm_group_label>
    <arm_group_label>T-I: very early tharpy in patients</arm_group_label>
    <arm_group_label>therapy in heterozygous carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>observational study!</description>
    <arm_group_label>T-III: late therapy in patients</arm_group_label>
    <arm_group_label>T-II: early therapy in patients</arm_group_label>
    <arm_group_label>T-I: very early tharpy in patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine and serum-samples.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Currently there are no causal therapeutic options which are proven to delay renal failure
        in AS. We established the European Alport Registry to collect data over several generations
        of Alport families across Europe. The different steps of disease enabled us to assess if
        earlier introduction of ACE-inhibition at earlier degrees of disease is more effective than
        later therapy in delaying the time to dialysis and improving life-expectancy.

        Heterozygous COL4A3/COL4A4 mutations result in the phenotype &quot;familial benign hematuria&quot; or
        &quot;thin basement membrane nephropathy&quot; (TBMN).

        For the first time, the present study compares the risk of renal impairment, end stage
        renal disease and premature death in between heterozygous carriers of XLAS and of ARAS
        mutations. Additionally, the nephroprotective effect of RAAS-blockade in patients with
        heterozygous Alport-mutations is evaluated.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria/ Exclusion Criteria:

        The diagnosis of Alport syndrome (AS) was proven by kidney biopsy or mutation analysis (or
        both). Patients were included if they were affected males with X-linked AS or patients with
        genetically proven homozygous autosomal AS. Patients were excluded if they did not give
        informed consent or the diagnosis was suspected but not confirmed.

        The diagnosis of the heterozygous status was proven by (1) mutation analysis or (2) kidney
        biopsy plus genetic consultation for decision in between XLAS or ARAS inheritance
        (including a conclusive genealogic tree and/or linkage analysis). Patients were excluded if
        they were affected males with XLAS or patients with genetically proven homozygous ARAS.
        Patients were excluded if they did not give informed consent or the diagnosis was suspected
        but not confirmed or if they donated a kidney (living donor to affected family member).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Gross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Goettingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oliver Gross, MD</last_name>
    <phone>+49-551-39-</phone>
    <phone_ext>6331</phone_ext>
    <email>gross.oliver@med.uni-goettingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Gross, MD</last_name>
      <phone>+49-551-39-</phone>
      <phone_ext>8912</phone_ext>
      <email>gross.oliver@med.uni-goettingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Temme J, Kramer A, Jager KJ, Lange K, Peters F, Müller GA, Kramar R, Heaf JG, Finne P, Palsson R, Reisæter AV, Hoitsma AJ, Metcalfe W, Postorino M, Zurriaga O, Santos JP, Ravani P, Jarraya F, Verrina E, Dekker FW, Gross O. Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. Clin J Am Soc Nephrol. 2012 Dec;7(12):1969-76. doi: 10.2215/CJN.02190312. Epub 2012 Sep 20.</citation>
    <PMID>22997344</PMID>
  </results_reference>
  <results_reference>
    <citation>Temme J, Peters F, Lange K, Pirson Y, Heidet L, Torra R, Grunfeld JP, Weber M, Licht C, Müller GA, Gross O. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int. 2012 Apr;81(8):779-83. doi: 10.1038/ki.2011.452. Epub 2012 Jan 11.</citation>
    <PMID>22237748</PMID>
  </results_reference>
  <results_reference>
    <citation>Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tönshoff B, Höcker B, Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher W, Dötsch J, Müller-Wiefel DE, Hoyer P; Study Group Members of the Gesellschaft für Pädiatrische Nephrologie, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, Müller GA, Weber M. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 2012 Mar;81(5):494-501. doi: 10.1038/ki.2011.407. Epub 2011 Dec 14.</citation>
    <PMID>22166847</PMID>
  </results_reference>
  <results_reference>
    <citation>Stock J, Kuenanz J, Glonke N, Sonntag J, Frese J, Tönshoff B, Höcker B, Hoppe B, Feldkötter M, Pape L, Lerch C, Wygoda S, Weber M, Müller GA, Gross O. Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations. Pediatr Nephrol. 2017 Jan;32(1):131-137. Epub 2016 Jul 11.</citation>
    <PMID>27402170</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Goettingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. O. Gross</investigator_full_name>
    <investigator_title>Prof. Dr. Oliver Gross</investigator_title>
  </responsible_party>
  <keyword>Alport syndrome</keyword>
  <keyword>thin basement membrane disease</keyword>
  <keyword>familial benign hematuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hematuria</mesh_term>
    <mesh_term>Nephritis, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

